XOMA Competitors and Similar CompaniesClear all
XOMA's competitors and similar companies include Humanigen, Novartis and Pfizer.
 XOMA XOMA is a biotechnology company discovering, developing and commercializing antibody-based therapeutics. |  Humanigen Humanigen is repositioning and developing its proprietary monoclonal antibodies to meet some critical unmet needs in cancer science. |  Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products. |  Pfizer Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products. | |
Founding Date | Founding Date 1981 | Founding Date 2000 | Founding Date 1996 | Founding Date 1849 |
Type | Type Public | Type Public | Type Public | Type Public |
Tags | ||||
Locations | Locations Emeryville, US HQ | Locations Burlingame, US HQ Dublin, IE London, GB Kansas City, US | Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more | Locations New York, US HQ Buenos Aires, AR Villa Adelina, AR Footscray, AU Mulgrave, AU Sydney, AU Wien, AT see more |
Employees | Employees 109% decrease | Employees 233% decrease | Employees 75,883 | Employees 81,0008% decrease |
Valuation ($) | Valuation ($) 353.7 m | Valuation ($) 4.3 m | Valuation ($) N/A | Valuation ($) 163.9 b |
Financial | ||||
Revenue (est.) | Revenue (est.) $52.1m (FY, 2025) | Revenue (est.) $2.5m (FY, 2022) | Revenue (est.) $56.7b (FY, 2025) | Revenue (est.) $62.6b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods $8.4b (FY, 2025) | Cost of goods $16.1b (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit $49.8b (FY, 2025) | Gross profit $46.5b (FY, 2025) |
Net income | Net income $31.7m (FY, 2025) | Net income ($70.7m) (FY, 2022) | Net income $14b (FY, 2025) | Net income $7.8b (FY, 2025) |
Operating ⚠ | ||||
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 44 (FY, 2022) | Phase III Trials Products 32 (FY, 2024) |
Registration Phase Products | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products 8 (FY, 2022) | Registration Phase Products 5 (FY, 2024) |
Funding | ||||
Total funding raised | Total funding raised N/A | Total funding raised $ 131.7m | Total funding raised $ 6.5m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Humanigen
HQ
Burlingame, US
Employees
2↓ 33% decrease
Humanigen is repositioning and developing its proprietary monoclonal antibodies to meet some critical unmet needs in cancer science.
View companyNovartis
HQ
Basel, CH
Employees
75,883
Novartis is a company that researches, develops, manufactures, and markets healthcare products.
View companyPfizer
HQ
New York, US
Employees
81,000↓ 8% decrease
Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.
View company